Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion

mAbs

Volumn 6, Issue 1, 2014, Pages 173-184

  Wagner Rousset, Elsa ^a   Janin Bussat, Marie Claire ^a   Colas, Olivier ^a   Excoffier, Melissa ^a   Ayoub, Daniel ^a   Haeuw, Jean François ^a   Rilatt, Ian ^a   Perez, Michel ^a   Corvaïa, Nathalie ^a   Beck, Alain ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

ADC; AFC; Antibody drug conjugates; Antibody fluorophore conjugates; DAR; IdeS; Mass spectrometry; Multimers; N linked glycosylation

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY FLUOROPHORE CONJUGATE; CYSTEINE; CYSTEINE PROTEINASE; DANSYL SULFONAMIDE ETHYLAMINE; DYE; IDES PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MALEIMIDE; SULFONAMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; 5-DIMETHYLAMINONAPHTHALENE-1-SULFONAMIDE; CYTOTOXIN; DANSYL AMIDE; DANSYL CHLORIDE; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; ARTICLE; CHROMATOGRAPHY; CONJUGATE; CONJUGATION; DRUG CONJUGATION; HUMAN; LIGHT CHAIN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; REDUCTION; CHEMICAL MODEL; CHEMISTRY; METHODOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHROMATOGRAPHY, LIQUID; CYSTEINE; CYTOTOXINS; DANSYL COMPOUNDS; HUMANS; IMMUNOCONJUGATES; MASS SPECTROMETRY; MODELS, CHEMICAL; PROTEOLYSIS;

EID: 84892595450     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26773     Document Type: Article

References (34)

1. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/ nri2747
2. Beck A, Senter P, Chari R. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 2011; 3:331-7; PMID:21691144; http://dx.doi.org/10.4161/ mabs.3.4.16612
3. Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs 2012; 4:637-47; PMID:22909934; http://dx.doi. org/10.4161/mabs.21697
4. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013; 12:329-32; PMID:23629491; http://dx.doi.org/10.1038/ nrd4009
5. Beck A, Carter PJ, Gerber HP, Lugovskoy AA, Wurch T, Junutula JR, et al. 8 (th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. MAbs. 2013; 5.
6. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329-39; PMID:21034674
7. Alley SC, Anderson KE. Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. Curr Opin Chem Biol 2013; 17:406-11; PMID:23570980; http://dx.doi.org/10.1016/j. cbpa.2013.03.022
8. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, Goetsch L, Wurch T, Van Dorsselaer A, Corvaïa N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9:482-501; PMID:19075687; http://dx.doi.org/10.2174/138920108786786411
9. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26:925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480
10. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30:184-9; PMID:22267010; http://dx.doi.org/10.1038/nbt.2108
11. Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013; 24:1256-63; PMID:23808985; http://dx.doi.org/10.1021/ bc400217g
12. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122:1455-63; PMID:23770776; http:// dx.doi.org/10.1182/blood-2013-03-491506
13. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011; 3:161-72; PMID:21441786; http://dx.doi.org/10.4161/ mabs.3.2.14960
14. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30:184-9; PMID:22267010; http://dx.doi.org/10.1038/nbt.2108
15. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, Ho WH, Farias S, Casas MG, Abdiche Y, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013; 20:161-7; PMID:23438745; http://dx.doi.org/10.1016/j. chembiol.2013.01.010
16. Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. MAbs 2012; 4:362-72; PMID:22531451; http://dx.doi. org/10.4161/mabs.19449
17. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A 2012; 109:16101-6; PMID:22988081; http://dx.doi.org/10.1073/ pnas.1211023109
18. Gianolio DA, Rouleau C, Bauta WE, Lovett D, Cantrell WR Jr., Recio A 3rd, Wolstenholme-Hogg P, Busch M, Pan P, Stefano JE, et al. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother Pharmacol 2012; 70:439-49; PMID:22821053; http://dx.doi.org/10.1007/ s00280-012-1925-8
19. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005; 16:1282-90; PMID:16173809; http://dx.doi.org/10.1021/ bc050201y (Pubitemid 41368132)
20. Le LN, Moore JM, Ouyang J, Chen X, Nguyen MD, Galush WJ. Profiling antibody drug conjugate positional isomers: a system-of-equations approach. Anal Chem 2012; 84:7479-86; PMID:22913809; http:// dx.doi.org/10.1021/ac301568f
21. Valliere-Douglass JF, McFee WA, Salas-Solano O. Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Anal Chem 2012; 84:2843-9; PMID:22384990; http://dx.doi.org/10.1021/ ac203346c
22. Chen J, Yin S, Wu Y, Ouyang J. Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates. Anal Chem 2013; 85:1699-704; PMID:23289544; http://dx.doi. org/10.1021/ac302959p
23. Rosati S, van den Bremer ET, Schuurman J, Parren PW, Kamerling JP, Heck AJ. In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. MAbs 2013; 5:915-22; PMID:23995615; http://dx.doi. org/10.4161/mabs.26282
24. von Pawel-Rammingen U, Johansson BP, Björck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002; 21:1607-15; PMID:11927545; http://dx.doi. org/10.1093/emboj/21.7. 1607 (Pubitemid 34614617)
25. Wenig K, Chatwell L, von Pawel-Rammingen U, Björck L, Huber R, Sondermann P. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc Natl Acad Sci U S A 2004; 101:17371-6; PMID:15574492; http:// dx.doi.org/10.1073/pnas.0407965101 (Pubitemid 39657411)
26. Vincents B, von Pawel-Rammingen U, Björck L, Abrahamson M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 2004; 43:15540-9; PMID:15581366; http://dx.doi. org/10.1021/bi048284d (Pubitemid 39647479)
27. Chevreux G, Tilly N, Bihoreau N. Fast analysis of recombinant monoclonal antibodies using IdeS proteolytic digestion and electrospray mass spectrometry. Anal Biochem 2011; 415:212-4; PMID:21596014; http://dx.doi.org/10.1016/j.ab. 2011.04.030
28. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier- Cianférani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; http://dx.doi. org/10.1021/ac3032355
29. Beck A, Diemer H, Ayoub D, Debaene F, Wagner-Rousset E, Carapito C, et al. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. TrAC Trends in Analytical Chemistry 2013; 48:81-95; http://dx.doi.org/10.1016/ j.trac.2013.02.014
30. Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner-Rousset E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottomup ESI and MALDI mass spectrometry techniques. MAbs 2013; 5:699-710; PMID:23924801; http:// dx.doi.org/10.4161/mabs.25423
31. Janin-Bussat MC, Tonini L, Huillet C, Colas O, Klinguer-Hamour C, Corvaïa N, et al. Cetuximab Fab and Fc N-Glycan Fast Characterization Using IdeS Digestion and Liquid Chromatography Coupled to Electrospray Ionization Mass Spectrometry. In: Beck A, editor. Glycosylation Engineering of Biopharmaceuticals. Springer, 2013.
32. Lynaugh H, Li H, Gong B. Rapid Fc glycosylation analysis of Fc fusions with IdeS and liquid chromatography mass spectrometry. MAbs 2013; 5:641-5; PMID:23839239; http://dx.doi.org/10.4161/ mabs.25302
33. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128:347-56; PMID:20730488; http://dx.doi.org/10.1007/ s10549-010-1090-x
34. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem 2010; 82:5219-26; PMID:20491447; http://dx.doi.org/10.1021/ac100575n